U.S. Hemoglobinopathies Market To Reach $6.85 Billion By 2030

U.S. Hemoglobinopathies Market Growth & Trends

The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.

The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies’ strengths can accelerate drug development and improve treatment outcomes.

 Request a free sample copy or view report summary: U.S. Hemoglobinopathies Market Report

U.S. Hemoglobinopathies Market Report Highlights

• Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.

• The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.

• The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.

• In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.

U.S. Hemoglobinopathies Market Segmentation

Grand View Research has segmented the U.S. hemoglobinopathies market based on type, diagnosis, therapy, and region:

U.S. Hemoglobinopathies Type Outlook (Revenue, USD Million, 2018 - 2030)

• Thalassemia

• Sickle Cell Disease

• Other Hemoglobin (Hb) Variants

U.S. Hemoglobinopathies Diagnosis Outlook (Revenue, USD Million, 2018 - 2030)

• Thalassemia

• Alpha

• Blood Test

• Genetic Test

• Prenatal Genetic Test

• Pre-implantation Genetic Diagnosis

• Electrophoresis

• Others

• Beta

• Blood Test

• Genetic Test

• Prenatal Genetic Test

• Pre-implantation Genetic Diagnosis

• Electrophoresis

• Others

• Sickle Cell Disease

• Blood Test

• Genetic Test

• Prenatal Genetic Test

• Electrophoresis

• Others

• (Hb) Variants

• Blood Test

• Genetic Test

• Prenatal Genetic Test

• Electrophoresis

• Others

U.S. Hemoglobinopathies Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Thalassemia

  • Alpha

    • Blood Transfusion

    • Iron Chelation Therapy

    • Bone Marrow Transplant

    • Others

  • Beta

    • Blood Transfusion

    • Iron Chelation Therapy

    • Bone Marrow Transplant

    • Others

• Sickle Cell Disease

  • Blood Transfusion

  • Hydroxyurea

  • Bone Marrow Transplant

  • Others

• (Hb) Variants

  • Blood Transfusion

  • Hydroxyurea

  • Bone Marrow Transplant

  • Others

U.S. Hemoglobinopathies Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Hemoglobinopathies Market

• Sangamo Therapeutics, Inc.

• Global Blood Therapeutics, Inc.

• bluebird bio, Inc.

• Emmaus Life Sciences Inc.

• Pfizer, Inc.

• Novartis AG

• Prolong Pharmaceuticals, LLC

• Bioverativ Inc.

• Celgene Corp.